{"disease":{"id":"paroxysmal-nocturnal-haemoglobinuria","name":"paroxysmal nocturnal haemoglobinuria"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06932744","title":"Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Wuhan Createrna Science and Technology Co., Ltd","has_results":false},{"nct_id":"NCT06633536","title":"Real-life Treatment Outcomes of Ravulizumab in PNH","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07052838","title":"Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}